Core B: Clinical Core

核心B：临床核心 摘要 密歇根州ADCC临床核心（CC）将利用强大的区域基础设施， 阿尔茨海默病（AD）和相关痴呆症的研究，重点是支持招募 ADCC的中心主题是识别、理解和调节非淀粉样蛋白因子， 脑功能障碍和神经退化。为了实现这些目标，CC招募并描述 参与者与其他核心，痴呆症相关诊所，当地联邦资助的中心（例如， Udall和Pepper中心）和地区阿尔茨海默氏症协会分会。除了保持一个 随着研究参与者注册人数的不断增加，CC将扩大一个已建立的近200人的纵向队列， 个体（56%非裔美国人），强调招募和表征那些最早的 认知能力下降的迹象我们以前和持续的UDS数据收集和参与国家 研究工作（例如，ADNI、ADCS）展示了我们对更大ADC网络的能力和承诺。 五个具体目标将加强对AD和相关痴呆症的研究。目标1将促进和加强 尖端的临床研究CC目前支持23项资助的临床试验和观察性研究 它涵盖了整个痴呆症谱，但强调认知丧失的最早标志物; NIA 这一指定将显著提高我们在三所参与大学推进AD研究的能力 包括ADCC。目标2将促进新的生物标志物研究。CC将评估已建立的 生物标志物（如神经影像学，脑脊液和遗传学），并扩大现有的联邦资助 合作评估潜在的新型生物标志物（脂质组学、磁共振波谱学和EEG） 光谱分析）。目标3将进一步加强少数民族参与老龄化和痴呆症研究， 包括利用与密歇根州合作建立的非常成功的底特律卫星诊所 非裔美国人老龄化研究中心。目标4将促进生物标志物转化为一般临床 实践为了解决疾病相关生物标志物的发现与其转化之间的关键差距， 在临床实践中，CC将与数据管理和统计核心（DMS）、外联和 招聘核心（OR）和研究教育组件核心（REC）开发产品和培训 项目来弥合这一翻译鸿沟。Aim 5将促进下一代痴呆症患者的培训 研究人员和临床医生。与区域经济委员会合作，协调委员会将利用综合资源， 为三个校区的早期职业调查人员提供多样化的培训机会 参与的大学。总之，协调委员会将把关键的机构和区域资源联系起来， 从早期发现到治疗干预的多学科研究。我们对少数民族的重视 招募，新的生物标志物，以及研究方法和发现的一般临床翻译 社区将支持密歇根州ADCC和更广泛的ADC网络内的研究新途径。

CORE B: CLINICAL CORE Abstract The Michigan ADCC Clinical Core (CC) will leverage a robust regional infrastructure to support and advance research on Alzheimer’s disease (AD) and related dementias, with an emphasis on recruitment that supports the ADCC's central theme of identifying, understanding and modulating the non-amyloid factors contributing to brain dysfunction and neurodegeneration. To accomplish these goals, the CC recruits and characterizes participants in collaboration with the other Cores, dementia-related clinics, local federally funded centers (e.g., Udall and Pepper Centers), and regional Alzheimer’s Association chapters. In addition to maintaining a growing registry of research participants, the CC will expand an established Longitudinal Cohort of nearly 200 individuals (56% African American), emphasizing the recruitment and characterization of those with the earliest signs of cognitive decline. Our previous and continued UDS data collection and participation in national research efforts (e.g., ADNI, ADCS) demonstrate our capability and commitment to the larger ADC network. Five specific aims will enhance research on AD and related dementias. Aim 1 will facilitate and enhance cutting-edge clinical research. The CC currently supports 23 funded clinical trials and observational studies that span the full dementia spectrum, yet place an emphasis on the earliest markers of cognitive loss; NIA designation will markedly enhance our capacity to advance AD research at the three participating universities comprising the ADCC. Aim 2 will promote novel biomarker research. The CC will assess established biomarkers (e.g. neuroimaging, cerebrospinal fluid, and genetics) and expand upon existing federally funded collaborations to evaluate potential novel biomarkers (lipidomics, magnetic resonance spectroscopy, and EEG spectral analysis). Aim 3 will further enhance ethnic minority participation in aging and dementia research, including leveraging a highly successful Detroit satellite clinic established in collaboration with the Michigan Center for African American Aging Research. Aim 4 will facilitate biomarker translation into general clinical practice. To address a critical gap between the discovery of disease-related biomarkers and their translation to clinical practice, the CC will work closely with the Data Management and Statistical Core (DMS), Outreach and Recruitment Core (OR) and Research Education Component Core (REC) to develop products and training programs to bridge this translational gap. Aim 5 will facilitate the training of the next generation of dementia researchers and clinicians. Collaborating with the REC, the CC will leverage the comprehensive resources and diverse training opportunities available for early career investigators across the campuses of the three participating universities. In summary, the CC will link critical institutional and regional resources to support multi-disciplinary research spanning from early detection to therapeutic intervention. Our emphasis on minority recruitment, novel biomarkers, and the translation of research methods and findings to the general clinical community will bolster new avenues of research within the Michigan ADCC and the broader ADC network.